RxDoctor Payments Data

Isaac Adatto, MD

Internal Medicine · Encino, CANPI 1437263845

Payments from drug & device makers

$477in general payments, 2019–2025

Across 23 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$160
  • Novo Nordisk$84
  • Johnson & Johnson$58
  • AstraZeneca$46
  • Teva Pharmaceuticals USA, Inc.$43
  • Boston Scientific$38
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$477 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$284,561
Medicare patients
377
Services billed
7,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$84,708
OzempicSemaglutide70$80,624
EliquisApixaban71$75,887
XareltoRivaroxaban28$46,756
MounjaroTirzepatide37$40,344
TradjentaLinagliptin21$21,414
JanuviaSitagliptin Phosphate21$19,878
Repatha SureclickEvolocumab14$13,246
MyrbetriqMirabegron14$9,867
SynthroidLevothyroxine Sodium82$7,811
Lagevrio (Eua)Molnupiravir12$7,194
Atorvastatin Calcium560$6,627
Dexlansoprazole DrDexlansoprazole20$6,575
Tresiba Flextouch U-100Insulin Degludec12$4,002
Rosuvastatin Calcium222$3,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$16$106,12277 claims
Novo NordiskOzempic$84$80,62470 claims
Johnson & JohnsonXarelto$58$46,75628 claims
MerckJanuvia, Lagevrio (Eua)$160$27,07233 claims
AbbVieSynthroid$18$7,81182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Encino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →